AndroGel and the Kidneys: Renal Protection or Renal Risk?

What Testosterone Actually Does to Kidney Physiology

Testosterone affects the kidney through at least three distinct pathways: erythropoietin stimulation, renin-angiotensin-aldosterone system (RAAS) modulation, and direct androgen-receptor signaling in renal tubular cells. Understanding each pathway is necessary before interpreting clinical trial data, because these mechanisms can push renal biomarkers in opposite directions at the same time.

Erythropoietin Stimulation and Hemoconcentration

Testosterone increases renal and hepatic erythropoietin (EPO) secretion, which raises red blood cell mass. In healthy men this is well tolerated. In men with stage 3 to 5 chronic kidney disease (CKD), who already have suppressed EPO, exogenous testosterone can produce disproportionate erythrocytosis because the EPO response is amplified against a lower background [1].

Polycythemia itself raises whole-blood viscosity, reduces renal plasma flow, and may contribute to glomerular hypertension. A hematocrit above 54% is listed as a contraindication in the FDA-approved AndroGel 1.62% prescribing information, and dose interruption is recommended when hematocrit exceeds 50% [2].

RAAS Activation and Sodium Retention

Testosterone upregulates angiotensinogen gene expression in the liver and modulates aldosterone secretion. This produces sodium and water retention, a finding visible as mild peripheral edema in approximately 3% of men in controlled AndroGel trials [2]. For a man with compensated heart failure or CKD-related volume overload, that 3% signal becomes clinically significant.

The same RAAS activation may raise blood pressure modestly, adding a secondary indirect insult to glomerular filtration over months to years of treatment.

Androgen Receptors in the Tubule

Renal tubular cells express androgen receptors, and animal models consistently show that testosterone promotes proximal tubular hypertrophy and modulates aquaporin channels [3]. Whether this translates to clinically meaningful changes in tubular function in humans is still being studied, but it provides biologic plausibility for the fluid-handling abnormalities seen in some men on TRT.

The T-Trials: What the Best Available Human Data Show

The Testosterone Trials (T-Trials) remain the most rigorous placebo-controlled dataset for testosterone gel in older hypogonadal men. Published in the New England Journal of Medicine in 2016, the T-Trials enrolled 788 men aged 65 or older with serum testosterone below 275 ng/dL and randomized them to AndroGel 1% (titrated to achieve levels of 500 to 1,000 ng/dL) or placebo gel for 12 months [4].

Primary Outcomes Relevant to Kidney Function

The T-Trials were not powered for renal endpoints. Renal function data were collected as safety assessments rather than pre-specified outcomes. Serum creatinine did not differ significantly between arms at 12 months. The testosterone group did show a statistically significant increase in hematocrit (mean rise of approximately 3 percentage points, P<0.001) compared with placebo, and polycythemia (hematocrit ≥54%) occurred in 5.8% of testosterone-treated men versus 0.8% of placebo men [4].

This erythrocytosis signal is directly relevant to renal plasma flow and viscosity, even though creatinine itself did not change at the group level.

Cardiovascular Signal and Its Renal Implications

The T-Trials also reported a non-significant numerical excess of cardiovascular events (major adverse cardiac events, or MACE) in the testosterone arm [4]. Because cardiac output and renal perfusion are tightly linked, any clinically meaningful reduction in cardiac function from a testosterone-related cardiovascular event would be expected to reduce GFR secondarily. This is the mechanism by which a drug's cardiovascular risk profile becomes a de-facto renal risk.

The Endocrine Society's 2018 Clinical Practice Guideline on male hypogonadism notes: "We suggest against testosterone therapy in men who have had a cardiovascular event in the past 6 months" [5]. Men with prior cardiovascular events are also the population most likely to have CKD, so this recommendation applies with particular force to the overlap population.

What T-Trials Did Not Tell Us

The T-Trials excluded men with eGFR below 30 mL/min/1.73 m² and those with uncontrolled hypertension, so the dataset cannot reliably inform prescribing in advanced CKD. Longer-term renal outcomes, proteinuria trajectories, and cystatin-C-based GFR changes were not reported.

Is There Any Evidence of Renal Protection?

The question of renal protection is not unreasonable. Hypogonadism is prevalent among men with CKD. Studies in populations on hemodialysis consistently find low testosterone levels, and testosterone deficiency correlates with muscle wasting, anemia, and worse dialysis outcomes. Some researchers have proposed that restoring testosterone might slow CKD progression through improvements in lean mass and insulin sensitivity.

Animal and Mechanistic Evidence

In rodent models of diabetic nephropathy, testosterone has been shown to reduce mesangial expansion and lower urinary albumin-to-creatinine ratios. However, these results have not been reproduced in human randomized controlled trials, and rodent androgen biology differs substantially from human physiology [3].

Observational Human Data

A 2021 cohort analysis published in the Journal of Clinical Endocrinology and Metabolism (JCEM) found that men with low serum testosterone (<300 ng/dL) had a 23% higher adjusted risk of incident CKD over 8 years compared with eugonadal men [6]. That association is hypothesis-generating, not causal. It could reflect reverse causation: CKD suppresses the hypothalamic-pituitary-gonadal axis, so low testosterone may be a consequence rather than a cause of declining renal function.

No phase 3 randomized trial has demonstrated that AndroGel or any testosterone formulation meaningfully reduces eGFR decline rate as a primary endpoint in men with CKD.

The HealthRX Renal-Risk Stratification Framework for Testosterone Gel

Clinicians at HealthRX use a three-tier approach when evaluating men for AndroGel who have known or suspected renal disease:

Tier 1 (Low renal risk): eGFR ≥60 mL/min/1.73 m², hematocrit <48%, no proteinuria, well-controlled blood pressure. Standard AndroGel dosing with hematocrit and creatinine checks at 3 and 6 months is appropriate.

Tier 2 (Moderate renal risk): eGFR 30 to 59 mL/min/1.73 m², or hematocrit 48 to 50%, or microalbuminuria (urine ACR 30 to 300 mg/g). Start at the lowest effective dose (AndroGel 1.62%, 1.25 g per actuation, one pump daily). Monitor hematocrit, creatinine, urine ACR, and blood pressure monthly for 3 months, then every 3 months.

Tier 3 (High renal risk): eGFR <30 mL/min/1.73 m², hematocrit ≥50% at baseline, macroalbuminuria, or active nephrotic syndrome. Testosterone gel is not contraindicated by the FDA label in CKD per se, but the risk-benefit ratio is unfavorable in most cases. Nephrology co-management before initiation is strongly advised, and injectable testosterone (which allows dose-hold without residual depot effect) may be preferable to a gel formulation where the 24-hour absorption window limits rapid discontinuation.

Pharmacokinetics of AndroGel Relevant to Renal Monitoring

AndroGel 1.62% applied at 40.5 mg (two pump actuations) reaches a mean steady-state serum testosterone of approximately 560 ng/dL in hypogonadal men [2]. The gel is absorbed transdermally over 24 hours, with peak serum levels roughly 2 hours after application. Renal clearance of testosterone itself is minimal because the liver metabolizes the vast majority to glucuronide and sulfate conjugates excreted in urine.

What Metabolite Excretion Means for CKD Patients

In men with advanced CKD, glucuronide conjugate clearance slows. This can lead to accumulation of testosterone metabolites, though whether this produces additional androgen-receptor stimulation or simply represents benign conjugate retention is not fully characterized [7]. Clinicians managing men with eGFR below 30 on any testosterone formulation should obtain steady-state serum testosterone levels (morning, 4 to 8 hours after application) more frequently than the standard 3-month interval.

Creatinine Interpretation Pitfalls

Testosterone increases muscle mass, which raises creatinine production independent of any change in GFR. A 5 to 10% rise in serum creatinine within the first 3 months of AndroGel does not automatically indicate nephrotoxicity. Cystatin-C-based eGFR, which is unaffected by muscle mass, provides a more accurate signal during TRT [8]. Ordering both creatinine and cystatin-C at baseline and at the 3-month mark allows the clinician to separate muscle-mass effects from genuine filtration changes.

Fluid Retention, Hypertension, and the Glomerular Pressure Cascade

Testosterone-mediated sodium retention is not simply a cosmetic concern. Sustained glomerular hypertension is the mechanism by which conditions like diabetes and obesity progressively scar glomeruli over years. If AndroGel raises systemic blood pressure by even 3 to 5 mmHg in a man who already has glomerular hypertension from diabetes, the additive effect on glomerular filtration pressure could accelerate albuminuria progression.

Blood Pressure Data from AndroGel Trials

The AndroGel 1.62% key trial (N=234 men) reported mean systolic blood pressure changes of less than 2 mmHg versus placebo [2]. That mean difference is reassuring at the population level. Individual-level responses, however, can be substantially larger, particularly in men with obesity, sleep apnea, or mineralocorticoid excess.

Practical Blood Pressure Management

Men starting AndroGel who have stage 2 hypertension (systolic ≥140 mmHg) should have blood pressure optimized before initiation. For men already on an ACE inhibitor or ARB for proteinuric CKD, the RAAS blockade provides some buffer against testosterone-mediated sodium retention. Still, a repeat blood pressure check at 4 to 6 weeks after starting AndroGel is prudent, especially in this subgroup.

Hematocrit Management: The Most Actionable Renal-Relevant Safety Parameter

Polycythemia is the most common laboratory adverse effect of AndroGel and the one most directly tied to renal plasma flow. The AndroGel 1.62% label states that hematocrit should be checked at 3 to 6 months after starting therapy, and then annually [2]. In men with CKD or cardiovascular disease, HealthRX clinicians shorten that to monthly for the first 3 months.

Dose Adjustment Algorithm

When hematocrit reaches 50 to 53%: reduce dose by one pump actuation and recheck in 4 weeks.

When hematocrit reaches 54% or above: stop AndroGel, recheck in 4 weeks, and resume at a lower dose only after hematocrit falls below 50%.

Therapeutic phlebotomy is sometimes used in men on injectable testosterone who develop severe polycythemia, but the 24-hour washout of a gel formulation usually makes dose reduction or temporary cessation sufficient [9].

Drug Interactions That Compound Renal Risk in AndroGel Users

Several drug classes frequently co-prescribed with TRT can amplify renal risk when combined with AndroGel.

NSAIDs

Non-steroidal anti-inflammatory drugs blunt prostaglandin-mediated afferent arteriolar dilation, reducing GFR acutely. Testosterone-driven volume expansion can worsen the hemodynamic effect of NSAIDs. Men on AndroGel should avoid chronic NSAID use and use acetaminophen as a first-line analgesic instead.

Erythropoiesis-Stimulating Agents

Men with CKD on dialysis may already receive darbepoetin or epoetin alfa. Adding AndroGel in this context stacks two EPO-stimulating mechanisms. Hematocrit can rise rapidly to dangerous levels. If testosterone gel is used in this population at all, erythropoiesis-stimulating agent doses should be reduced proactively, per nephrology guidance.

Corticosteroids

Systemic corticosteroids produce independent sodium retention and can potentiate the fluid-retention effect of testosterone. A man taking prednisone 20 mg daily for an inflammatory condition who then starts AndroGel may accumulate 3 to 4 liters of extracellular fluid within weeks. Monitoring weight weekly for the first month helps catch this early.

Special Populations: CKD Stages 3B to 5 and Dialysis

The FDA label for AndroGel does not list CKD as a contraindication, but evidence for safety in stages 3B to 5 (eGFR <45 mL/min/1.73 m²) is sparse. A 2019 Cochrane review of testosterone supplementation in men with CKD identified only four small randomized trials (combined N=187) and found insufficient evidence to draw conclusions about either efficacy or renal safety [10].

Dialysis patients represent a separate category. Testosterone levels are low in 60 to 70% of men on hemodialysis, largely due to uremic suppression of LH and FSH. Observational data from hemodialysis cohorts suggest that low testosterone associates with higher all-cause mortality, but no adequately powered RCT has established that correcting it with AndroGel improves survival or reduces cardiovascular events in this population [6].

Until randomized evidence exists, prescribing AndroGel to men on dialysis should be a shared decision made jointly with the patient's nephrologist, with the explicit acknowledgment that efficacy and safety data are limited.

Current Guideline Positions on Testosterone and Kidney Disease

The Endocrine Society 2018 guideline on male hypogonadism does not explicitly address CKD-specific dosing but recommends against initiating testosterone in men with "conditions that might be exacerbated by testosterone, including polycythemia, untreated obstructive sleep apnea, and heart failure with NYHA class III or IV" [5]. CKD frequently coexists with all three of those conditions.

The American Urological Association 2022 testosterone deficiency guideline recommends that clinicians "assess baseline hematocrit, prostate-specific antigen, and lipid profile before initiating testosterone therapy" and monitor hematocrit at follow-up visits [11]. No CKD-specific monitoring protocol is specified, which leaves the gap that the HealthRX tiered framework above is designed to fill.

The 2012 KDIGO CKD guideline does not address TRT specifically but emphasizes that any agent affecting blood pressure, fluid balance, or RAAS activity requires careful monitoring in CKD [12].

Practical Takeaways for Prescribers and Patients

Men with confirmed symptomatic hypogonadism and normal or mildly reduced kidney function (eGFR ≥60) can use AndroGel with standard monitoring, provided blood pressure is controlled and they understand the hematocrit risk. Men in stages 3 to 4 CKD need more frequent monitoring, lower starting doses, and coordinated care with nephrology. For men on dialysis, the conversation should include honest acknowledgment that RCT evidence for benefit is absent.

The creatinine-rise trap deserves a final mention. A man who starts AndroGel, gains 2 kg of lean mass over 12 weeks, and then sees his creatinine rise from 1.1 to 1.3 mg/dL has likely experienced muscle-mass-driven creatinine production, not true GFR loss. Check cystatin-C before concluding that AndroGel harmed his kidneys.